Germany - Pharmaceuticals

For more information and to make a bid you will need to go to the third party website.

Details

Provided by Open Opps
Opportunity closing date
15 August 2022
Opportunity publication date
05 May 2020
Category
33600000: Pharmaceutical products
Value of contract
to be confirmed
Your guide to exporting
Report opportunity

Description

Conclusion of non-exclusive discount agreements according to § 130 a para. 8 SGB V with the possibility of conclusion at any time within the framework of so-called "open house procedures" for various active pharmaceutical ingredients with the earliest possible contract start on 1.10.2020.The concrete active pharmaceutical ingredients and the respective contract start dates can be found in the current list of active pharmaceutical ingredients in the project room of the awarding portal dtvp under the heading "Award documents".as of 1.10.2020, contracts will be offered for the following active substances:- Abacavir;- Abacavir/Dolutegravir/Lamivudine;- Abacavir/Lamivudine/Zidovudine;- Abatacept;- Acetylcysteine RX;- Acetylcysteine non-RX;- Acetylsalicylic acid exclusively products that can be prescribed according to Annex 1 AM-RL G-BA;- Acitretin;- Adalimumab;- Agomelatin;- Alitretionin;- Ambrisentan;- Amphotericin B;- Anagrelide with the exception of N3-packs of DAR HKP with 0.5 mg active strength;- Apomorphine;- aprepitant;- aripiprazole except DAR tablets/melting tablets and solutions for ingestion;- atazanavir;- atomoxetine;- benazepril/HCT;- bimatoprost;- biperides;- bortezomib;- bosentan;- brivudine;- calcipotriol;- calcium/colecalciferol;- capsaicin DAR patches;- chlorprothixes;- cinacalcet;- cinnarizine/dimenhydrinate;- clostridium botulinum;- clotrimazole;- colecalciferol non-RX;- colecalciferol RX;- colistin;- cyproterone;- dabigatran;- dalteparin;- denosumab oncological indication;- denosumab orthopaedic indication;- desloratadine;- desogestrel/ethinylestradiol;- dienogest;- dienogestrell/estradiol;- dienogestrell/ethinylestradiol;- distigmine;- dolutegravir;- dornase alpha;- drospirenone/ethinylestradiol;- dutasteride/tamsulosin;- ebastine;- edoxaban;- efavirenz/emtricitabin/tenofovir;- iron II oral DAR/only products prescribable according to Annex 1 AM-RL G-BA;- emtricitabine;- emtricitabin/tenofovirdisoproxil/ripivirin;- enoxaparin 20 mg and 40 mg potency;- enoxaparin 60 mg, 80 mg and 100 mg potency;- erlotinib;- erythropoietin epoetin;- estradiol;- etanercept;- etravirin;- febuxostat;- fentanyl except DAR matrix patches (transdermal patches);- filgrastim;- flupentixol decanoate;- fluvastatin;- follitropin alfa;- follitropin beta;- fondaparinux sodium;- fosamprenavir;- fosfomycin;- fulvestrant;- fusidic acid;- fusidic acid/betamethasone;- gefitinib;- glatiramer acetate except 40 mg active strength;- goserelin;- hydrocortisone;- hydromorphone DAR injection/infusion solution;- hydroxychloroquine;- hydroxyzine;- immunoglobulins normal human, intravascular use;- Infliximab;- Interferon beta 1a Avonex(R);- Irbesartan;- Ivabradine;- Ketorolac;- Lenograstim;- Leuprorelin;- Lidocaine DAR patch;- Lipegfilgrastim;- Loperamid;- Lopinavir/Ritonavir;- Macrogol exclusively products which are prescribable according to Annex 1 AM-RL G-BA;- Macrogol exclusively medical devices which are prescribable according to Annex 5 AM-RL G-BA;- Meloxicam;- Meropenem;- Methocarbamol with the exception of DAR film-coated tablets with 750 mg active substance strength;- Midazolam;- Miglustat;- Nadroparin;- Naftidrofuryl;- Natalizumab;- Nifedipine;- Nitrofurantoin;- octreotide;- oxycodone/naloxone;- paliperidone;- palonosetron DAR soft capsules;- pancreatin;- paracetamol exclusively according to Annex 1 AM-RL G-BA prescription products;- pegfilgrastim;- peginterferon alpha-2a;- peginterferon beta-1a;- pemetrexed;- perindopril/indapamide;- piroxicam;- posaconazole;- progesterone except DAR soft capsules;- promethazine;- pyridostigmine;- Rabeprazole;- Raltegravir;- Ritonavir;- Rituximab;- Rotigotine;- Rupatadine;- Salmeterol;- Saquinavir;- Solifenacin;- Somatropin;- Sorafenib;- Sulfasalazine;- Tacrolimus amtl. ATC: L04AD02;- Tadalafil Ind. pulmonary hypertension;- Tapentadol;- Taurolidine exclusively according to Annex V AM-RL G-BA prescription-capable medical devices;- Teriparatide;- Tiotropium bromide Inh.Inh;- Tiotropium bromide Inh.lsg;- Tobramycin;- Tolvaptan;- Tramadol/Paracetamol;- Trastuzumab;- Travoprost;- Travoprost/Timololol;- Triptorelin;- Valsartan/Amlodipine;- Zidovudine.The contracts end uniformly on 30.9.2022.
The AOK Rhineland/Hamburg announces the conclusion of non-exclusive discount agreements according to § 130 a para. 8 SGB V with the possibility of conclusion at any time within the scope of so-called "open house procedures" for various active pharmaceutical ingredients with the earliest possible start of the contract on 1.10.2020.The specific active pharmaceutical ingredients and the respective earliest possible start of the contract can be found in the current list of active pharmaceutical ingredients in the project room of the dtvp award portal under the heading "Award Documents". 8 SGB V.Interested pharmaceutical companies can obtain the participation documents in the project room of the DTVP Awarding Portal under the heading "Award Documents".The prerequisite for the conclusion of a contract is that the interested pharmaceutical company sends the requested participation documents completely filled out and signed to the following e-mail box: open-house@rh.aok.de.This e-mail box is used for any exchange of documents and records for the implementation of the open-house procedure between the companies and the Pharmaceuticals/Pharmacies division of the AOK Rheinland/Hamburg.A contract is concluded with each pharmaceutical company that fulfils the participation requirements. Exclusivity is not granted. Membership or the conclusion of a contract can take place at any time and under the same conditions. Individual contract negotiations will not be conducted. The earliest contract start date is 1.10.2020. The conclusion of or accession to a discount contract is possible at any time, i.e. also after 1.10.2020. The contract period ends uniformly on 30.9.2022, regardless of the individual contract start date. In this case, all companies verified in the Project Space on the DTVP procurement portal will receive an e-mail with a note indicating which active substances have been added and when the respective, earliest possible contract start date is.if the AOK Rhineland/Hamburg conducts a tender for exclusive contracts in the form of the open procedure during the contract period, the contracts concluded within the scope of this publication will be terminated in accordance with the contractual provisions.This publication does not constitute the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EC) or public procurement law. In order to ensure the highest degree of transparency for the intended conclusion of contracts, publication is made in the Supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice is used, and the resulting conceptual specifications, such as the procedural designation "open procedure", are solely due to the use of this notice form and the publication platform. This does not imply any further significance, in particular submission to regulations under public procurement law, unless they are obligated for legal reasons.

Opportunity closing date
15 August 2022
Value of contract
to be confirmed

About the buyer

Address
AOK Rheinland/Hamburg — Die Gesundheitskasse Kasernenstr. 61 Düsseldorf 40213 Germany
Contact
open-house@rh.aok.de

The deadline to apply for this opportunity has passed.
Visit the opportunities page to find another.

Is there anything wrong with this page?